What’s Really Keeping New Drug Discoveries from Getting Through the Clinical Trials Pipeline? The Answer May Surprise You

BOSTON, MA – AUGUST 15, 2002 – Clinical trials are inextricably linked to the pharmaceutical industry – touching many aspects of drug discovery, development and commercialization. However, the costs associated with collecting, managing and analyzing the enormous amounts of data needed to support the development of just one new drug is overwhelming.


Making investments in new technologies to automate and streamline the clinical trials process could significantly decrease the time and cost of bringing new therapies to market. In fact, PricewaterhouseCoopers estimates that in silico methods applied throughout the drug discovery and development timeline could save $200 million and two years for each drug reaching the market.

A special report in the August issue of IDG's Bio-IT World entitled, "Clinical Trial Data Management: Tortured by Paper," takes an in-depth look at bottlenecks caused by the disparity between the innovative nature of drug discovery, and the pharmaceutical industry's antiquated reliance on paper trails to chronicle the clinical trials process. Senior science editor Mark Uehling led the report that addresses critical questions including:

What factors are slowing the adoption of new data management tools, collaboration software and networking equipment in the pharmaceutical industry?

How do pharmaceutical executives and clinical trial investigators balance their primary focus – the safe, effective acceleration of drug discovery and clinical trial processes – with identifying technologies and solutions to manage and leverage the data?

How dominant is the problem of managing clinical trial data, what are the associated costs and concerns?

Could clinical trials truly become a paperless process?

Why do pharmaceutical companies have limited ability to dictate broad technological change in the labs and hospitals supporting their trials?

What IT companies are successfully affecting change in this industry? What barriers to adoption have they had to overcome?

What impact will the FDA regulation known as Title 21 CFR Part 11 have on driving new technology investments to keep better electronic records?

What impact does the two-year open position at the head of the FDA have on the life sciences industry and the IT companies supplying solutions to this market?

To access this article online, visit www.bio-itworld.com. Additionally, if you are interested in speaking with the author, Bio-IT World senior science editor Mark Uehling, please contact Liz Campbell at The Portico Group at (781) 541-6504 or lcampbell@theporticogroup.com.

About Bio-IT World, Inc.

A business unit of IDG, Bio-IT World, Inc. provides information products and services to meet the needs of bio-IT professionals focused on strategic IT applications in the life sciences. The company's premiere publication, Bio-IT World, and accompanying website, www.bio-itworld.com, deliver the latest news, analysis and information on the technology infrastructure and applications driving innovation in the bio-IT community. Established in September 2001, Bio-IT World, Inc. is headquartered in Framingham, Mass.

About IDG

Bio-IT World is a business unit of IDG, the world's leading technology media, research and event company. IDG publishes more than 300 magazines and newspapers and offers online users the largest network of technology-specific sites around the world through IDG.net (www.idg.net), which comprises more than 330 targeted Web sites in 80 countries. IDG is also a leading producer of 168 computer-related events worldwide, and IDG's research company, IDC, provides global market intelligence and advice through 51 offices in 43 countries. Company information is available at www.idg.com.


# # #